Biotech PR: What It Is and 6 Agencies Worth Knowing (2026)

Biotech PR is the communications work that builds scientific, regulatory and financial credibility for companies developing drugs, gene therapies, diagnostics and devices. It serves investors, regulators, clinicians, patients and partners at once, under SEC disclosure rules and FDA limits on promotion. Specialist agencies such as LifeSci Communications, LaVoieHealthScience, Russo Partners, Spectrum Science and Real Chemistry run much of it.

Updated October 20, 2026.

What is biotech PR?

Biotech PR is the discipline of communicating a company's science, clinical progress and business position to the audiences that decide its future. Because a biotech product can take years to reach market, much of the work is sustaining confidence between milestones, such as trial readouts, financings and regulatory decisions.

Who does biotech PR talk to?

Biotech PR talks to five audiences, and each one needs different information through different channels.

How do SEC and FDA rules shape biotech PR?

SEC and FDA rules limit what a biotech company can say and when. Public companies must disclose material information fairly under the SEC's Regulation FD, which requires that it reach all investors at the same time. The FDA restricts promotion of prescription drugs: promotional claims must be balanced with risk information, and companies cannot promote unapproved uses.

For that reason, a communications team coordinates with legal, regulatory affairs and clinical operations before each announcement. A statement that would be routine in technology PR can create a compliance problem in biotech.

How is biotech PR different from technology PR?

• Time horizon: development runs for years, from preclinical work through trials and approval, so communications has to hold interest across long gaps.
• Regulated claims: what a company may say about a product is limited by regulators, not only by brand preference.
• Trust stakes: patients, doctors and investors commit health, prescribing decisions and capital based on what the company says.
• Scientific publication: peer-reviewed journals and medical meetings are part of the credibility record in a way they are not for most technology brands.

What are the main functions of a biotech PR team?

• Investor and analyst communications around financings, earnings and pipeline updates.
• Regulatory milestone communications, including advisory committee meetings, approvals and Complete Response Letters.
• Scientific and medical communications, including publications, conference programs and relationships with key opinion leaders.
• Clinical trial communications, from trial launch through interim analyses and primary endpoint readouts.
• Patient advocacy and community engagement.
• Corporate, M&A and crisis communications.
• Visibility in AI answers, since clinicians, patients and investors increasingly research companies in ChatGPT, Claude, Perplexity, Gemini and Google AI Overviews.

Which agencies run biotech PR?

Six agencies are worth knowing, grouped by the type of work they suit. This is a guide to agency types, not a ranking.

The ranked comparison of 20 healthcare and biotech firms is in Best Healthcare and Biotech PR Agencies in 2026.

How should a biotech company choose an agency by stage?

A biotech company should match the agency type to its stage, because the communications job changes at each one.

• Development-stage and pre-IPO: choose a specialist that handles investor relations, since clinical milestones and financings drive the work.
• Late-stage with regulatory milestones: choose a science-first independent that can pair compliant messaging with media relations around FDA actions.
• Commercial-stage launch: choose a healthcare network with prescriber, payer and patient advocacy reach.
• Any stage competing in AI answers: add a capability that tracks how often the company is named in AI engines.

What mistakes recur in biotech communications?

Five mistakes recur in biotech communications failures.

• Overpromising at clinical readouts, when the positioning does not survive later regulatory review or peer analysis.
• Founder-led storytelling that runs ahead of the science. Theranos dissolved in 2018, and a federal jury convicted founder Elizabeth Holmes of fraud in January 2022. EPR covers the pattern in health PR failures.
• No plan for safety signals, so the first communication about a drug safety issue is made under pressure. The classic product-safety case is the Tylenol crisis of 1982.
• Patient advocacy that reads as marketing instead of a long-term relationship.
• Ignoring AI answers, which clinicians and patients increasingly use to research companies.

How is biotech PR measured?

Biotech PR is measured through investor and analyst sentiment, engagement at scientific conferences, pickup of peer-reviewed publications, share of voice in medical and business press, clinician awareness, and how often the company is named in AI answers. Teams track each against a baseline set before a milestone so the effect of the communications can be seen.

How much does biotech PR cost?

EPR estimates full-service biotech retainers at $20,000 to $60,000 per month, with IPO and milestone work priced as projects on top. The figure comes from EPR's pricing analysis in Best Healthcare and Biotech PR Agencies in 2026 and is an estimate, not a published rate card.

Related coverage

• Healthcare PR: strategy, firms and crisis
• Best healthcare and biotech PR agencies in 2026
• Pharma public relations guide
• Healthcare GEO
• GLP-1 communications brief